Lung Cancer :: Lung cancer survival better in nonsmokers
Never-smokers with early stage lung cancer have significantly better survival than smokers with the disease.
Never-smokers with early stage lung cancer have significantly better survival than smokers with the disease.
Variations in two genes related to inflammation may be a major risk factor for developing lung cancer, according to a team of scientists from the National Cancer Institute and the University of Texas M. D. Anderson Cancer Center.
Patients with inoperable non-small cell lung cancer who receive an initial high dose of chemotherapy before their treatment begins can expect an increase in overall survival, according to a study in the July 1 issue of the International Journal of Radiation Oncology, Biology, Physics, the official journal of ASTRO.
Researchers at UT Southwestern Medical Center have determined how a substance derived from the bark of the South American lapacho tree kills certain kinds of cancer cells, findings that also suggest a novel treatment for the most common type of lung cancer.
Arsenic exposure appears to continue causing lung and bladder cancer deaths years after exposure ends, according to a study published online June 12 in the Journal of the National Cancer Institute.
Some patients with advanced non?small-cell lung cancer (NSCLC) have slightly higher survival rates when treated with the chemotherapy drug cisplatin than another platinum-based drug, carboplatin, according to a study in the June 6 Journal of the National Cancer Institute.
GlaxoSmithKline (GSK) announced final results of a Phase II proof-of-concept clinical trial of its investigational MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) in MAGE-A3 positive patients with stage IB or II Non-Small Cell Lung Cancer (NSCLC).
Talcum powder has been used for generations to soothe babies? diaper rash and freshen women?s faces. But University of Florida researchers report the household product has an additional healing power: The ability to stunt cancer growth by cutting the flow of blood to metastatic lung tumors.
Two research teams have developed models for classifying the clinical outcomes of patients with nonsmall cell lung cancer using mass spectrometry techniques. The studies are published in the June 6 Journal of the National Cancer Institute.
A multi-center team, led by Vanderbilt-Ingram Cancer Center investigators, has discovered a ?signature? of proteins in the blood that predicts which non-small-cell lung cancer patients will live longer when they are treated with certain targeted cancer therapies.